Eileen Higham PhD, BSE

Eileen Higham has more than two decades of experience in academia and industry, leveraging deep technical, strategic, and operational expertise to develop innovative cell therapies, gene therapies, and biologics to transform human health. She is currently Senior Vice President, and Head of Technical Operations at Intergalactic Therapeutics. Before joining Intergalactic, Eileen was Vice President, Head of Analytical & Process Development at Sana Biotechnology, where she led a team developing best-in-class manufacturing processes and analytical packages for the production of next-generation cell and gene therapies. Prior to Sana, Eileen was Senior Director, Head of Analytical & Process Development at Juno Therapeutics (Celgene/Bristol Myers Squibb), where she provided technical, strategic, and operational leadership for development of best-in-class manufacturing processes and analytical packages for the production of autologous T cell therapies. In this role, she built and led an organization of 100+ scientists and engineers developing strategies to enable robust, well-controlled, scalable, and well-characterized Drug Product process design and associated analytical packages to support Phase 0 through commercialization. Prior to Juno, Eileen served as Associate Director/Product Development Team Leader - Adoptive Cellular Therapy at MedImmune/AstraZeneca, with joint appointments in Biopharmaceutical Development (BPD) and the Oncology Innovative Medicines Unit (iMED). She started her career in the industry at Merck as a Biochemical Engineer developing in-house, serum-free cell culture media to derisk large scale production of viral vaccines. Eileen received a B.S. in Engineering in Chemical Engineering from Princeton University and a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology.